## Justin C Mcarthur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4077418/publications.pdf

Version: 2024-02-01

274 papers 18,628 citations

71 h-index 133 g-index

296 all docs 296 docs citations

296 times ranked 10230 citing authors

#	Article	IF	CITATIONS
1	ANA Webinars: Clinical and basic research resilience during COVIDâ€19. Annals of Clinical and Translational Neurology, 2021, 8, 302-304.	3.7	O
2	Sudden Sensorineural Hearing and Vestibular Loss in a Case of Relapsing Polychondritis. Annals of Otology, Rhinology and Laryngology, 2021, 130, 000348942110059.	1.1	3
3	Large Mitochondrial DNA Deletions in HIV Sensory Neuropathy. Neurology, 2021, 97, e156-e165.	1.1	5
4	Remembrance of Things Past: A Critical Step in Changing our Future. Annals of Neurology, 2021, 90, 521-523.	5.3	1
5	Strengthened through Diversity: A Blueprint for Organizational Change. Annals of Neurology, 2021, 90, 524-536.	5.3	4
6	Chronic inflammation mediates brain injury in HIV infection: relevance for cure strategies. Current Opinion in Neurology, 2020, 33, 397-404.	3.6	34
7	Ingrained Injustice: The <scp>ANA</scp> Responds. Annals of Neurology, 2020, 88, 207-208.	5.3	1
8	â€~A man is as old as his arteries' (attributed to Thomas Sydenham, the English Hippocrates). Aids, 2020, 34, 637-639.	2.2	2
9	Neurological manifestations associated with COVID-19: a review and a call for action. Journal of Neurology, 2020, 267, 1573-1576.	3.6	110
10	The Path Forward: Academic Neurology Responds to <scp>COVID</scp> â€19. Annals of Neurology, 2020, 87, 789-793.	5.3	7
11	Hindsight Is 20/20. Journal of Hospital Medicine, 2020, 15, 245-249.	1.4	O
12	Efficacy and safety of two-drug regimens for treatment of HIV in the central nervous system. Aids, 2020, 34, 1975-1977.	2.2	2
13	Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 34, 100-102.	2.0	7
14	Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV,the, 2019, 6, e456-e462.	4.7	15
15	Solitary sclerosis presenting as isolated spontaneous paroxysmal dysarthria. ENeurologicalSci, 2019, 14, 98-100.	1.3	6
16	Impaired insulin sensitivity is associated with worsening cognition in HIV-infected patients. Neurology, 2019, 92, e1344-e1353.	1.1	9
17	Clinician-rated measures for distal symmetrical axonal polyneuropathy. Neurology, 2019, 93, 346-360.	1.1	19
18	Intranasal insulin therapy reverses hippocampal dendritic injury and cognitive impairment in a model of HIV-associated neurocognitive disorders in EcoHIV-infected mice. Aids, 2019, 33, 973-984.	2.2	37

#	Article	IF	CITATIONS
19	Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy. Aids, 2019, 33, S145-S157.	2.2	85
20	Distinguishing cognitive impairment from HIV-associated neurocognitive disorder versus substance use?. Aids, 2019, 33, 1943-1944.	2.2	4
21	Cognitive Trajectory Phenotypes in Human Immunodeficiency Virus–Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 61-70.	2.1	18
22	Advanced Pediatric Neurosonography Techniques: Contrastâ€Enhanced Ultrasonography, Elastography, and Beyond. Journal of Neuroimaging, 2018, 28, 150-157.	2.0	15
23	Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial. Journal of NeuroVirology, 2018, 24, 16-27.	2.1	34
24	Hemochromatosis ( <i>HFE</i> ) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2018, 34, 942-949.	1.1	4
25	PML in natalizumab-treated multiple sclerosis. Neurology, 2017, 88, 1110-1111.	1.1	4
26	The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations. Journal of Pain, 2017, 18, 757-777.	1.4	115
27	Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. Journal of Neuroinflammation, 2017, 14, 72.	7.2	30
28	Treatment of human immunodeficiency virus-related peripheral neuropathy with Scrambler Therapy: a case report. International Journal of STD and AIDS, 2017, 28, 202-204.	1.1	20
29	Pearls and Pitfalls, Part 2. Seminars in Neurology, 2016, 36, 407-408.	1.4	0
30	Pearls and Pitfalls, Part 1. Seminars in Neurology, 2016, 36, 315-316.	1.4	0
31	HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment. Nature Reviews Neurology, 2016, 12, 234-248.	10.1	690
32	Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era. Journal of Infectious Diseases, 2016, 213, 1065-1073.	4.0	31
33	Neuroinflammation and Virus Replication in the Spinal Cord of Simian Immunodeficiency Virus–Infected Macaques. Journal of Neuropathology and Experimental Neurology, 2015, 74, 38-47.	1.7	18
34	Pathobiology of CNS Human Immunodeficiency Virus Infection. , 2015, , 444-466.		1
35	Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology, 2015, 84, 241-250.	1.1	40
36	Cerebrospinal fluid metabolomics implicate bioenergetic adaptation as a neural mechanism regulating shifts in cognitive states of HIV-infected patients. Aids, 2015, 29, 559-569.	2.2	56

#	Article	IF	Citations
37	Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. Journal of NeuroVirology, 2015, 21, 525-534.	2.1	14
38	CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease. Journal of NeuroVirology, 2015, 21, 559-567.	2.1	36
39	CNS infections in 2014: guns, germs, and will. Lancet Neurology, The, 2015, 14, 20-22.	10.2	0
40	Cambinol, a Novel Inhibitor of Neutral Sphingomyelinase 2 Shows Neuroprotective Properties. PLoS ONE, 2015, 10, e0124481.	2.5	77
41	Genetic Variation in Iron Metabolism Is Associated with Neuropathic Pain and Pain Severity in HIV-Infected Patients on Antiretroviral Therapy. PLoS ONE, 2014, 9, e103123.	2.5	29
42	Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. Journal of NeuroVirology, 2014, 20, 457-465.	2.1	21
43	The Armadillo as a Model for Peripheral Neuropathy in Leprosy. ILAR Journal, 2014, 54, 304-314.	1.8	43
44	Controversies in HIV-associated neurocognitive disorders. Lancet Neurology, The, 2014, 13, 1139-1151.	10.2	242
45	MITOCHONDRIAL MUTATIONS IN HIV-ASSOCIATED SENSORY NEUROPATHY. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.135-e4.	1.9	0
46	Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology, 2014, 82, 2055-2062.	1.1	255
47	Characterizing HIV Medication Adherence for Virologic Success Among Individuals Living With HIV/AIDS: Experience With the CNS HIV Antiretroviral Therapy Effects Research ( <i>CHARTER</i> ) Cohort. Journal of HIV/AIDS and Social Services, 2014, 13, 8-25.	0.7	6
48	Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. Journal of NeuroVirology, 2013, 19, 393-401.	2.1	38
49	A novel computerized functional assessment for human immunodeficiency virus-associated neurocognitive disorder. Journal of NeuroVirology, 2013, 19, 432-441.	2.1	17
50	Emerging Infections of the Central Nervous System. Current Infectious Disease Reports, 2013, 15, 576-582.	3.0	12
51	Neurologic Complications and Considerations in HIV-Infected Persons. Current Infectious Disease Reports, 2013, 15, 61-66.	3.0	16
52	Older individuals with HIV infection have greater memory deficits than younger individuals. Journal of NeuroVirology, 2013, 19, 531-536.	2.1	27
53	Sleep, Function and HIV: A Multi-Method Assessment. AIDS and Behavior, 2013, 17, 2808-2815.	2.7	58
54	A lipid storage–like disorder contributes to cognitive decline in HIV-infected subjects. Neurology, 2013, 81, 1492-1499.	1.1	53

#	Article	IF	CITATIONS
55	Ethnic differences in epidermal nerve fiber density. Muscle and Nerve, 2013, 48, 462-464.	2.2	17
56	Evaluating Sleep and Cognition in HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 609-616.	2.1	51
57	Painful Small Fiber Neuropathies. CONTINUUM Lifelong Learning in Neurology, 2012, 18, 106-125.	0.8	15
58	A comparative evaluation of quantitative neuroimaging measurements of brain status in HIV infection. Psychiatry Research - Neuroimaging, 2012, 203, 95-99.	1.8	16
59	Health-Related Quality of Life â€~Well-Being' in HIV Distal Neuropathic Pain is More Strongly Associated with Depression Severity than with Pain Intensity. Psychosomatics, 2012, 53, 380-386.	2.5	40
60	Neurologic disorders incidence in HIV+ vs HIVâ^' men. Neurology, 2012, 79, 1873-1880.	1.1	61
61	Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz. Journal of Pharmacology and Experimental Therapeutics, 2012, 343, 696-703.	2.5	114
62	HIV-Associated Neurological Disorders. CNS Drugs, 2012, 26, 123-134.	5.9	69
63	SIV-induced impairment of neurovascular repair: a potential role for VEGF. Journal of NeuroVirology, 2012, 18, 222-230.	2.1	13
64	Macrophage-Mediated Dorsal Root Ganglion Damage Precedes Altered Nerve Conduction in SIV-Infected Macaques. American Journal of Pathology, 2011, 179, 2337-2345.	3.8	49
65	CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. Aids, 2011, 25, 1747-1751.	2.2	345
66	A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2011, 17, 159-165.	2.1	46
67	John W. "Jack―Griffin, MD. Annals of Neurology, 2011, 69, A11-A13.	<b>5.</b> 3	1
68	Impaired neurovascular repair in subjects with diabetes following experimental intracutaneous axotomy. Brain, 2011, 134, 1853-1863.	7.6	77
69	Peripheral neuropathy in HIV: prevalence and risk factors. Aids, 2011, 25, 919-928.	2.2	171
70	Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. Journal of NeuroVirology, 2010, 16, 445-456.	2.1	29
71	Human immunodeficiency virusâ€associated neurocognitive disorders: Mind the gap. Annals of Neurology, 2010, 67, 699-714.	<b>5.</b> 3	382
72	Biomarkers of neurological status in HIV infection: A 3â€year study. Proteomics - Clinical Applications, 2010, 4, 295-303.	1.6	23

#	Article	IF	CITATIONS
73	Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral Therapy. Archives of Neurology, 2010, 67, 552.	4.5	347
74	Comparison of scales to evaluate the progression of HIV-associated neurocognitive disorder. HIV Therapy, 2010, 4, 371-379.	0.6	33
75	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids, 2009, 23, 1359-1366.	2.2	305
76	Mirtazapine Use in Human Immunodeficiency Virus–Infected Patients With Progressive Multifocal Leukoencephalopathy. Archives of Neurology, 2009, 66, 255-8.	4.5	99
77	Extensive astrocyte infection is prominent in human immunodeficiency virus–associated dementia. Annals of Neurology, 2009, 66, 253-258.	5.3	313
78	Altered cutaneous nerve regeneration in a simian immunodeficiency virus / macaque intracutaneous axotomy model. Journal of Comparative Neurology, 2009, 514, 272-283.	1.6	20
79	Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System. Archives of Neurology, 2008, 65, 65.	4.5	777
80	Evolution of HIV dementia with HIV infection. International Review of Psychiatry, 2008, 20, 25-31.	2.8	111
81	Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. HIV Clinical Trials, 2008, 9, 434-439.	2.0	15
82	An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection. Archives of Neurology, 2007, 64, 97.	4.5	95
83	Molecular programming of endothelinâ€1 in HIVâ€infected brain: role of Tat in upâ€regulation of ETâ€1 and its inhibition by statins. FASEB Journal, 2007, 21, 777-789.	0.5	40
84	Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain, 2007, 130, 2703-2714.	7.6	110
85	Platelet Decline. Archives of Neurology, 2007, 64, 1264.	4.5	37
86	The prevalence and incidence of neurocognitive impairment in the HAART era. Aids, 2007, 21, 1915-1921.	2.2	539
87	Assessment of Epidermal Nerve Fibers. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1059-073.	1.7	125
88	AIDS dementia complex in China. Journal of Clinical Neuroscience, 2007, 14, 8-11.	1.5	5
89	A Randomized Trial Evaluating Prosaptideâ,,¢ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. PLoS ONE, 2007, 2, e551.	2.5	36
90	The Role of Cohort Studies in Drug Development: Clinical Evidence of Antiviral Activity of Serotonin Reuptake Inhibitors and HMG-CoA Reductase Inhibitors in the Central Nervous System. Journal of NeuroImmune Pharmacology, 2007, 2, 120-127.	4.1	38

#	Article	IF	Citations
91	Prevalence of human immunodeficiency virus–associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. Journal of NeuroVirology, 2006, 12, 356-364.	2.1	80
92	Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle and Nerve, 2006, 34, 53-56.	2.2	83
93	Is the Glass Threeâ€Quarters Full or Oneâ€Quarter Empty?. Journal of Infectious Diseases, 2006, 194, 1628-1631.	4.0	6
94	Undetectable Cerebrospinal Fluid HIV RNA and $\hat{I}^2$ -2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 426-429.	2.1	58
95	Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. Journal of NeuroVirology, 2005, 11, 346-355.	2.1	100
96	Neurological complications of HIV infection. Lancet Neurology, The, 2005, 4, 543-555.	10.2	507
97	Another tool for the neurologist's toolbox. Annals of Neurology, 2005, 57, 163-167.	5.3	21
98	Pathology and Quantitation of Cutaneous Innervation. , 2005, , 869-895.		72
99	Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. Neurology, 2005, 65, 1778-1781.	1.1	136
100	The reliability of skin biopsy with measurement of intraepidermal nerve fiber density. Journal of the Neurological Sciences, 2005, 228, 65-69.	0.6	123
101	The International HIV Dementia Scale: a new rapid screening test for HIV dementia. Aids, 2005, 19, 1367-74.	2.2	282
102	The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain, 2004, 127, 1606-1615.	7.6	334
103	Amyloid precursor protein expression in circulating monocytes and brain macrophages from patients with HIV-associated cognitive impairment. Journal of Neuroimmunology, 2004, 157, 99-110.	2.3	28
104	HIV dementia: an evolving disease. Journal of Neuroimmunology, 2004, 157, 3-10.	2.3	390
105	Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Annals of Neurology, 2004, 55, 257-267.	5.3	241
106	Attenuated Central Nervous System Infection in Advanced HIV/AIDS With Combination Antiretroviral Therapy. Archives of Neurology, 2004, 61, 1687.	4.5	125
107	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	2.1	370
108	Epidermal reinnervation after intracutaneous axotomy in man. Journal of Comparative Neurology, 2003, 457, 24-36.	1.6	90

#	Article	IF	CITATIONS
109	FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Annals of Neurology, 2003, 53, 57-64.	5.3	77
110	Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Annals of Neurology, 2003, 54, 287-296.	5.3	177
111	Nucleoside analogues and neuropathy in the era of HAART. Journal of Clinical Virology, 2003, 26, 195-207.	3.1	80
112	New Insights Into Diabetic Polyneuropathy. JAMA - Journal of the American Medical Association, 2003, 290, 1371.	7.4	116
113	Human Immunodeficiency Virus-Associated Dementia: An Evolving Disease. Journal of NeuroVirology, 2003, 9, 205-221.	2.1	22
114	HIV-associated sensory neuropathies. Aids, 2002, 16, 2105-2117.	2.2	194
115	Through a Glass, Darkly. Archives of Neurology, 2002, 59, 909.	4.5	35
116	Pathophysiology of nervous system diseases. , 2002, , 3-13.		0
117	Genetics of common neurological disorders. , 2002, , 14-31.		1
118	Repeat expansion and neurological disease. , 2002, , 32-54.		4
119	Cell birth and cell death in the central nervous system. , 2002, , 55-61.		0
120	Neuroprotection in cerebral ischemia., 2002,, 62-78.		0
121	Promoting recovery of neurological function. , 2002, , 79-104.		O
122	Measurement of neurological outcomes. , 2002, , 105-117.		2
123	Principles of clinical neuro-epidemiology. , 2002, , 118-126.		O
124	Principles of therapeutics. , 2002, , 127-130.		0
125	Windows on the working brain: functional imaging. , 2002, , 131-145.		O
126	Windows on the working brain: magnetic resonance spectroscopy. , 2002, , 146-159.		0

#	Article	IF	CITATIONS
127	Windows on the working brain: evoked potentials, magnetencephalography and depth recording. , 2002, , $160-174$ .		O
128	Congenital disorders of cerebral cortical development. , 2002, , 177-194.		0
129	The aging brain: morphology, imaging and function. , 2002, , 195-209.		O
130	Neurodegenerative diseases., 2002,, 210-236.		3
131	Aging and dementia: principles, evaluation and diagnosis. , 2002, , 237-251.		1
132	Dementia with Lewy bodies., 2002,, 267-282.		0
133	Frontotemporal dementia., 2002,, 283-288.		O
134	Consciousness and its disorders. , 2002, , 289-300.		0
135	Mechanisms of memory and amnestic syndromes. , 2002, , 301-316.		O
136	Acquired disorders of language. , 2002, , 317-330.		0
137	Neglect., 2002,, 331-347.		O
138	Disorders of mood. , 2002, , 364-373.		0
139	Obsessive–compulsive disorder. , 2002, , 385-405.		O
140	Autism and autistic spectrum disorders. , 2002, , 406-421.		0
141	Attention deficit hyperactivity disorder: spectrum and mechanisms. , 2002, , 422-430.		O
142	The neurobiology of drug addition., 2002,, 431-446.		2
143	Mechanisms of motor control. , 2002, , 449-461.		O
144	The apraxias. , 2002, , 462-476.		0

#	Article	IF	CITATIONS
145	Other extrapyramidal syndromes: parkinsonism-plus and other forms of secondary parkinsonism., 2002,, 490-512.		1
146	Tremors. , 2002, , 513-522.		0
147	Myoclonus., 2002,, 523-531.		O
148	Tourette syndrome. , 2002, , 551-567.		0
149	Gait and balance disorders. , 2002, , 581-592.		3
150	Smell. , 2002, , 595-609.		1
151	Disorders of vision. , 2002, , 621-633.		O
152	Oculomotor control: normal and abnormal. , 2002, , 634-657.		2
153	Disorders of the auditory system. , 2002, , 658-677.		O
154	Vertigo and vestibular disorders. , 2002, , 678-692.		4
155	Spinal cord injury and repair., 2002,, 695-712.		O
156	Myelopathies., 2002,, 713-726.		0
157	Diseases of the vertebral column. , 2002, , 727-741.		O
158	Cervical pain. , 2002, , 742-759.		2
159	Diagnosis and management of low back pain. , 2002, , 760-770.		1
160	Autonomic function and dysfunction. , 2002, , 773-794.		0
161	Human brain–gut interactions: mechanisms of swallowing, visceral perception, and anal continence in health and disease. , 2002, , 795-807.		O
162	Eating disorders: neurobiology and symptomatology. , 2002, , 808-815.		1

#	Article	IF	CITATIONS
163	Sleep and its disorders., 2002,, 816-832.		0
164	Bladder and sexual dysfunction. , 2002, , 833-852.		0
165	Hypothalamic/pituitary function and dysfunction. , 2002, , 853-870.		O
166	Peripheral nociception and the genesis of persistent clinical pain., 2002,, 873-887.		0
167	Central nervous system mechanisms of pain. , 2002, , 888-905.		10
168	Management of chronic pain., 2002,, 906-919.		1
169	Cluster headache, other trigeminal autonomic syndromes and the short-lived headaches. , 2002, , 927-938.		1
170	Orofacial pain. , 2002, , 939-954.		0
171	Chronic daily headache., 2002,, 955-972.		0
172	Pathophysiology of nerve and root disorders. , 2002, , 1075-1091.		3
173	Toxic and metabolic neuropathies. , 2002, , 1092-1109.		0
174	Guillain–Barré syndrome. , 2002, , 1110-1128.		1
175	Hereditary neuropathies., 2002,, 1129-1142.		0
176	Disorders of neuromuscular junction transmission. , 2002, , 1143-1162.		2
177	Disorders of striated muscle. , 2002, , 1163-1182.		0
178	Pathophysiology of myotonia and periodic paralysis. , 2002, , 1183-1206.		5
179	Pathophysiology of metabolic myopathies. , 2002, , 1207-1226.		O
180	The cellular basis of epilepsy., 2002, , 1229-1247.		0

#	Article	IF	CITATIONS
181	The clinical spectrum of epilepsy., 2002,, 1248-1270.		O
182	Assessment of the patient with epilepsy. , 2002, , 1281-1300.		O
183	Principles of pharmacotherapy of the epilepsies. , 2002, , 1301-1312.		3
184	Epilepsy surgery: disease treatment and investigative opportunity., 2002,, 1313-1334.		0
185	Physiology of the cerebral circulation. , 2002, , 1337-1344.		O
186	Stroke syndromes., 2002,, 1345-1360.		0
187	The treatment of acute ischemic stroke. , 2002, , 1361-1370.		O
188	Behavioural manifestations of stroke. , 2002, , 1371-1382.		0
189	Aneurysms and arteriovenous malformations. , 2002, , 1392-1404.		3
190	Hereditary causes of stroke. , 2002, , 1405-1414.		0
191	Preventive management of stroke. , 2002, , 1415-1428.		O
192	Primary brain tumours in adults., 2002,, 1431-1447.		3
193	Brain tumours in children. , 2002, , 1448-1461.		O
194	Brain metastases. , 2002, , 1462-1473.		2
195	Paraneoplastic syndromes., 2002,, 1474-1488.		0
196	Harmful effects of radiation on the nervous system. , 2002, , 1489-1498.		0
197	Immune mechanisms in neurological disease. , 2002, , 1501-1526.		1
198	The basis of immunotherapy in neurological disease. , 2002, , 1527-1546.		0

#	Article	IF	CITATIONS
199	Vasculitis of the central nervous system. , 2002, , 1547-1557.		О
200	Sarcoidosis of the nervous system., 2002,, 1558-1568.		0
201	Collagen–vascular disease and the nervous system. , 2002, , 1569-1590.		0
202	Myelination, demyelination and remyelination., 2002, , 1593-1605.		1
203	Multiple sclerosis and its pathophysiology. , 2002, , 1606-1619.		4
204	The diagnosis and management of multiple sclerosis., 2002,, 1620-1632.		0
205	Leukodystrophies. , 2002, , 1633-1648.		0
206	Host responses in central nervous system infection. , 2002, , 1651-1659.		0
207	Viral diseases of the nervous system. , 2002, , 1660-1682.		3
208	Neurological manifestations of HIV infection. , 2002, , 1683-1709.		0
209	Neurological manifestations of HTLV-I infection. , 2002, , 1710-1715.		O
210	Clinical features of human prion diseases. , 2002, , 1716-1727.		2
211	Parasitic disease., 2002,, 1745-1753.		2
212	Head trauma. , 2002, , 1793-1804.		0
213	Environmental toxins and neurological disease. , 2002, , 1805-1813.		O
214	Alcohol neurotoxicity., 2002,, 1814-1826.		4
215	Neurological consequences of drug abuse. , 2002, , 1827-1838.		0
216	Genetically engineered models of neurodegenerative diseases. , 2002, , 1841-1862.		1

#	Article	IF	CITATIONS
217	Motor neuron disease. , 2002, , 1863-1879.		O
218	The hereditary ataxias. , 2002, , 1880-1895.		3
219	Huntington's disease., 2002,, 1896-1910.		0
220	Progressive cerebral degeneration of childhood., 2002,, 1911-1921.		0
221	Mitochondrial encephalomyopathies., 2002,, 1922-1936.		0
222	Neurological aspects of pregnancy. , 2002, , 1939-1951.		0
223	The brain and the cardiovascular system. , 2002, , 1952-1969.		0
224	Neurological complications of hepatic and gastrointestinal disease., 2002,, 1970-1986.		0
225	Renal disease and electrolyte disturbances. , 2002, , 1987-2015.		0
226	Disorders of intracranial pressure. , 2002, , 2016-2032.		0
227	Neurologic manifestations of endocrine disease. , 2002, , 2033-2043.		0
228	Neurological manifestations of hematological diseases. , 2002, , 2044-2060.		0
229	Neurocutaneous syndromes. , 2002, , 2061-2081.		0
230	Neurological complications after organ transplantation. , 2002, , 2082-2092.		0
231	Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. Aids, 2002, 16, 407-412.	2.2	81
232	HIV-associated cognitive impairment before and after the advent of combination therapy. Journal of NeuroVirology, 2002, 8, 136-142.	2.1	555
233	Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. Aids Reader, 2002, 12, 29-31, 38.	0.3	25
234	Progression of HIV-associated dementia treated with HAART. Aids Reader, 2002, 12, 69-74.	0.3	44

#	Article	IF	CITATIONS
235	Assessment of cutaneous innervation by skin biopsies. Current Opinion in Neurology, 2001, 14, 655-659.	3.6	64
236	HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. Journal of the Peripheral Nervous System, 2001, 6, 21-27.	3.1	230
237	Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Annals of Neurology, 2001, 49, 745-752.	5.3	152
238	Increased frequency of the tumor necrosis factor-?-308 a allele in adults with human immunodeficiency virus dementia. Annals of Neurology, 2001, 50, 157-162.	5.3	88
239	HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity. Journal of NeuroVirology, 2001, 7, 235-249.	2.1	49
240	HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. Aids, 2001, 15, 747-751.	2.2	47
241	Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. Journal of NeuroVirology, 2000, 6, 84-88.	2.1	97
242	Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. Aids, 2000, 14, 273-278.	2.2	167
243	Cytotoxicity by Matrix Metalloprotease-1 in Organotypic Spinal Cord and Dissociated Neuronal Cultures. Experimental Neurology, 2000, 163, 324-330.	4.1	73
244	Rate and Severity of HIV-Associated Dementia (HAD): Correlations with Gp41 and iNOS. Molecular Medicine, 1999, 5, 98-109.	4.4	88
245	Cerebrospinal fluid levels of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Annals of Neurology, 1999, 46, 391-398.	5.3	197
246	Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy. Journal of the Neurological Sciences, 1999, 164, 172-178.	0.6	167
247	Smallâ€fiber sensory neuropathies: Clinical course and neuropathology of idiopathic cases. Annals of Neurology, 1998, 44, 47-59.	5.3	319
248	?-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Annals of Neurology, 1998, 44, 831-835.	5.3	330
249	Failure of Cytarabine in Progressive Multifocal Leukoencephalopathy Associated with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 1345-1351.	27.0	343
250	Epidermal Nerve Fiber Density. Archives of Neurology, 1998, 55, 1513.	4.5	518
251	Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. Journal of Neuroimmunology, 1997, 74, 1-8.	2.3	158
252	Relationship between human immunodeficiency virus—associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 1997, 42, 689-698.	5.3	392

#	Article	IF	CITATIONS
253	Stereological Analysis of Cerebral Atrophy in Human Immunodeficiency Virus-associated Dementia. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1032-1037.	1.7	29
254	Epidermal denervation and its effects on keratinocytes and Langerhans cells. Journal of Neurocytology, 1996, 25, 513-524.	1.5	125
255	Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Annals of Neurology, 1996, 39, 705-711.	5.3	415
256	A Quantitative MRI Study of the Basal Ganglia in Depression in HIV Seropositive Men. Journal of Neuro-AIDS, 1996, 1, 29-41.	0.2	6
257	Adequately Treated Remote Syphilis Does Not Augment CNS HIV-1 Expression. Journal of Neuro-AIDS, 1996, 1, 87-96.	0.2	0
258	Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia. Annals of Neurology, 1995, 38, 755-762.	5.3	661
259	HIV Dementia Scale: A Rapid Screening Test. Journal of Acquired Immune Deficiency Syndromes, 1995, 8, 273-278.	0.3	302
260	Normative Data for a Brief Neuropsychologic Test Battery in a Cohort of Injecting Drug Users. Substance Use and Misuse, 1995, 30, 823-841.	0.6	28
261	Clinicopathologic correlations of HIVâ€1â€associated vacuolar myelopathy. Neurology, 1994, 44, 2159-2159.	1.1	126
262	Elevated central nervous system prostaglandins in human immunodeficiency virus?associated dementia. Annals of Neurology, 1994, 35, 592-597.	5.3	221
263	Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia. Acta Neuropathologica, 1994, 88, 538-544.	7.7	7
264	Clinicalâ€neuropathologic correlation in HIVâ€associated dementia. Neurology, 1993, 43, 2230-2230.	1.1	312
265			

#	Article	IF	CITATIONS
271	The neurobiology of human immunodeficiency virus infections. FASEB Journal, 1988, 2, 2970-2981.	0.5	149
272	Neurologic Manifestations of AIDS. Medicine (United States), 1987, 66, 407-437.	1.0	396
273	Central Nervous System Complications of Human Immunodeficiency Virus. The American Journal of EEG Technology, 1987, 27, 33-49.	0.3	3
274	Univariate and Multivariate Analyses of the Mental Status Examination. Journal of the American Geriatrics Society, 1985, 33, 483-488.	2.6	123